Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men worldwide. It is a heterogeneous disease at molecular and clinical levels which makes its prognosis and treatment outcome hard to predict. The epithelial-to-mesenchymal transition (EMT) marks a key step in the invasion and malignant progression of PCa. We sought to assess the co-expression of epithelial cytokeratin 8 (CK8) and mesenchymal vimentin (Vim) in locally-advanced PCa as indicators of EMT and consequently predictors of the progression status of the disease.Methods: Co-expression of CK8 and Vim was evaluated by immunofluorescence (IF) on paraffin-embedded tissue sections of 122 patients with PCa who underwent radical prostatectomies be...
Prostate cancer is the second leading cause of cancer-related deaths in American men. Most of these ...
The aim of the present study was to investigate the prognostic role of metallothionein-2A (MT-2A), E...
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men wil...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Prostate cancer (PCa) is the most common cancer in men and the third most common cause of cancer-rel...
Purpose: The prognostic efficiency of clinical grading and staging in patients with confined or mode...
Abstract 54 Background: Identification of potentially lethal disease at the time of diagnosis with ...
PURPOSE: Transforming growth factor-beta (TGF-beta)-mediated epithelial-to-mesenchymal transition (E...
Purpose: Transforming growth factor-beta (TGF-beta)-mediated epithelial-to-mesenchymal transition (E...
Epithelial-to-mesenchymal transition (EMT) is a process known to be associated with aggressive tumor...
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men wil...
Background: Metastatic prostate cancer (PCa) has no curative treatment options. Some forms of PCa ar...
Prostate cancer is the second leading cause of cancer-related deaths in American men. Most of these ...
The aim of the present study was to investigate the prognostic role of metallothionein-2A (MT-2A), E...
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men wil...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Background: Prostate cancer (PCa) is the second most frequent cause of cancer-related death in men w...
Prostate cancer (PCa) is the most common cancer in men and the third most common cause of cancer-rel...
Purpose: The prognostic efficiency of clinical grading and staging in patients with confined or mode...
Abstract 54 Background: Identification of potentially lethal disease at the time of diagnosis with ...
PURPOSE: Transforming growth factor-beta (TGF-beta)-mediated epithelial-to-mesenchymal transition (E...
Purpose: Transforming growth factor-beta (TGF-beta)-mediated epithelial-to-mesenchymal transition (E...
Epithelial-to-mesenchymal transition (EMT) is a process known to be associated with aggressive tumor...
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men wil...
Background: Metastatic prostate cancer (PCa) has no curative treatment options. Some forms of PCa ar...
Prostate cancer is the second leading cause of cancer-related deaths in American men. Most of these ...
The aim of the present study was to investigate the prognostic role of metallothionein-2A (MT-2A), E...
Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men wil...